A Comparative study of the activation peptide of carboxypeptidase B and trypsinogen as early predictors of the severity of acute pancreatitis

Pancreas

Volumn 29, Issue 1, 2004, Pages

  Saez S ^a   Martinez J ^a   Trigo, C ^a   Sanchez Paya J ^a   Grioo P ^a   Company L ^a   Laveda, R ^a   Penalva, J C ^a   Garcia C ^a   Perez Mateo M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Activation peptide of carboxypeptidase B; Acute pancreatitis; Assessment of severity; Prognostic markers; Urinary trypsinogen activation peptide

Indexed keywords

BIOLOGICAL MARKER; CARBOXYPEPTIDASE B; CARBOXYPEPTIDASE B ACTIVATION PEPTIDE; OLIGOPEPTIDE; PEPTIDE; TRYPSINOGEN; TRYPSINOGEN ACTIVATION PEPTIDE;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; ENZYME ACTIVATION; EVALUATION; FEMALE; HOSPITALIZATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREATITIS; PREDICTION AND FORECASTING; PROGNOSIS; PROSPECTIVE STUDY; ROC CURVE; URINE;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; AGED; BIOLOGICAL MARKERS; CARBOXYPEPTIDASE B; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PANCREATITIS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TRYPSINOGEN;

EID: 6044229232     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/00006676-200407000-00062     Document Type: Article

References (26)

1. Dervenis C, Johnson CD, Bassi C, et al. Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini Consensus Conference. Int J Pancreatol. 1999;25:195-210.
2. Martínez J, Sanchez-Payá J, Palazón JM, et al. Obesity: a prognostic factor of severity in acute pancreatitis. Pancreas. 1999;19:15-20.
3. Viedma JA, Pérez-Mateo M, Agulló J, et al. Inflammatory response in the early prediction of severity in human acute pancreatitis. Gut. 1994;35:822-827.
4. Ranson JHC, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974;139:69-81.
5. Blamey SL, Imrie CW, O’Neill J, et al. Prognostic factors in acute pancreatitis. Gut. 1984;25:1340-1346.
6. Borgström A, Appelros S. Activation peptides in acute pancreatitis. In: Buchler MW, Uhl W, Friess H, et al., eds. Acute Pancreatitis. Novel Concepts in Biology and Therapy. Berlin-Vienna: Blackwell Wissenschafts-Verlag; 1999:219-223.
7. Frossard JL. Trypsin activation peptide (TAP) in acute pancreatitis: from pathophysiology to clinical usefulness. JOP. 2001;2:69-77.
8. Gudgeon AM, Heath DI, Hurley P, et al. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet. 1990;335:4-8.
9. Tenner S, Fernández-del Castillo C, Warshaw A, et al. Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis. Int J Pancreatol. 1997;21:105-110.
10. Neoptolemos JP, Kemppainen EA, Mayer JM, et al. Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. Lancet. 2000;355:1955-160.
11. Khan Z, Vlodov J, Horovitz J, et al. Urinary trypsinogen activation peptide is more accurate than hematocrit in determining severity in patients with acute pancreatitis: a prospective study. Am J Gastroenterol. 2002; 97:1973-1977.
12. Lempinen M, Stenman UH, Finne P, et al. Trypsinogen-2 and trypsinogen activation peptide (TAP) in urine of patients with acute pancreatitis. J Surg Res. 2003;111:267-273.
13. Appelros S, Thim L, Borgström A. Activation peptide of carboxypeptidase B in serum and urine acute pancreatitis. Gut. 1998;42:97-102.
14. Appelros S, Petersson U, Toh S, et al. Activation peptide of carboxypeptidase B and anionic trypsinogen as early predictors of the severity of acute pancreatitis. Br J Surg. 2001;88:216-221.
15. Pezzilli R, Morselli-Labate AM, Barbieri AR, et al. Clinical usefulness of the serum carboxypeptidase B activation peptide in acute pancreatitis. JOP. 2000;1:58-68.
16. Ung CT, Westlake S, Brennan H, et al. Activation peptide of carboxy peptidase B (CAPAP) for prediction of complicated acute pancreatitis "abstract". Digestion. 2000;61:289.
17. Muller CA, Appelros S, Uhl W, et al. Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic disease. Gut. 2002;51:229-235.
18. Bradley EL III. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128:586-590.
19. Neoptolemos JP, Raraty M, Finch M, et al. Acute pancreatitis: the substantial human and financial cases. Gut. 1998;42:486-491.
20. McKay CJ, Evans S, Sinclair M, et al. High early mortality rate from acute pancreatitis in Scotland, 1984-1995. Br J Surg. 1999;86:1302-1305.
21. Pederzoli P, Bassi C, Vesentini S, et al. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet. 1993;176:480-483.
22. Bassi C, Falconi M, Talamini G, et al. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology. 1998; 115:1513-1517.
23. Fölsch UR, Nitsche R, Lüdtke R, et al. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. N Engl J Med. 1997;336:237-242.
24. Fernández-del Castillo C, Harringer W, Warshaw AL, et al. Risk factors for pancreatic cellular injury after cardiopulmonary bypass. N Engl J Med. 1991;325:382-387.
25. Banks PA, Carr-Locke DL, Slivka A, et al. Urinary trypsinogen activation peptides (TAP) are not increased in mild ERCP-induced pancreatitis. Pancreas. 1996;12:294-297.
26. Hofbauer B, Saluja AK, Lerch MM, et al. Intra-acinar cell activation of trypsinogen during caerulein-induced pancreatitis in rats. Am J Physiol. 1998;275:G352-G362.